Palbociclib Capsule shortage
To Be Discontinued 2 presentations · 1 manufacturers · first FDA posting 2026-04-22 · last update 2026-04-22
Manufacturers: Pfizer Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Ibrance, Capsule, 75 mg (NDC 0069-0187-21) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured. | Posted 04/22/2026 Updated 04/22/2026 Discontinued 04/22/2026 |
| Ibrance, Capsule, 100 mg (NDC 0069-0188-21) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured. | Posted 04/22/2026 Updated 04/22/2026 Discontinued 04/22/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)